FDA Updates

NEW GENERICS

Consumers aren't making the most of their relationship with their pharmacist.

Consumers aren't making the most of their relationship with their pharmacist.

NEW DRUGS

New products (Rx, OTC, HBC, HHC, and ETC.) for DRUG TOPICS, September 13, 2004

Stockchecker on antacids.

DEA proposes security requirements for manufacturers, distributors, importers and exporters of pseudoephedrine, ephedrine and PPA

APha and J&J Merck launch American Pharmacists Month in October

New products (Rx, OTC, HHC, HBC, ETC.) for the Aug. 23, 2004 issue of DRUG TOPICS.

McKesson rolls out FrontEdge Merchandiser program to help independents increase sales.

New cough/cold/flu/sore throat remedies are ready for fall/winter 2004.

New products: Rx, OTC, etc., for DRUG TOPICS Aug. 9, '04

lice treatments as kids head back to school 2004

Adverse drug reactions worldwide have prompted the World Health Organization to release new guidelines

The FDA recently approved codeine/chlorpheniramine (Codeprex, Celltech Group) extended-release suspension (CIII) for the temporary relief of cough, as may occur with the common cold or inhaled irritants, and for the temporary relief of runny nose; sneezing; itching of the nose or throat; and itchy, watery eyes due to hay fever, other upper respiratory allergies, or allergic rhinitis. The product is expected to be available in retail pharmacies by the fourth quarter.

New drugs, new indications, new generics, OTCs, health & beauty care, etc. (Includes ad index)

Medicare launches program for beneficiaries with serious and chronic illnesses

Men's pricey skincare lines debut from Gillette, SC Johnson, KMI, and Neutrogena.

National Consumers League and FDA launch take with care campaign about safety when taking otcs

New products from Rx to OTC

Office of Inspector General isues demand letter to PharMerica Drug Systems based on alleged kickback violations, damages total $21.8 million

Manufacturers are unleashing a slew of battery operated otcs

Stockchecker on cough and cold

New Product Newswire

Clinicians can now offer their patients the first nonsystemic, gastrointestinal selective antibiotic to receive FDA approval. The agency recently approved rifaximin (Xifaxan, Salix Pharmaceuticals) tablets for the treatment of TD caused by noninvasive strains of Escherichia coli in those 12 years of age or older. Rifaximin is currently approved for use in 17 countries worldwide. It is expected to be available in U.S. pharmacies in August.

Top OTCs provided by Information Resources Inc, Chicago

Nail polish makers Estee lauder and Procter & Gamble reformulate nail polishes--take DBP pthalate out amid health concerns

New Product Newswire